Bone Metastasis in Prostate Cancer: Bone Scan Versus PET Imaging

Mohseninia, Nasibeh; Zamani-Siahkali, Nazanin; Harsini, Sara; Divband, Ghasemali; Pirich, Christian; Beheshti, Mohsen

doi:10.1053/j.semnuclmed.2023.07.004

Cited by 8 publications

(7 citation statements)

References 160 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…BM significantly influences patients' treatments and prognosis (25). To date, Bone scan has been widely used diagnostic method and the most frequent examination for BM diagnosis (5).Combined with whole-body bone single-photon emission computed tomography and computed tomography, SPECT/CT aids in reducing superimposition from activity, thereby leading to enhanced anatomical localization and a clearer distinction ability, which proves to be a more precise technique in comparison to planar bone scan (6,7). Although with high precision in diagnosing BM, not all PCa patients benefit from bone scan.…”

Section: Discussionmentioning

confidence: 99%

“…Bone metastasis (BM) was the prominent metastatic event in PCa, which was regarded as an adverse factor for survival and quality of life (3,4). Currently, bone scan including single-photon emission computed tomography and computed tomography (SPECT/CT) has been widely used for diagnosing BM of PCa, with 92% sensitivity and 95% specificity (5)(6)(7). The incidence of BM is 11%-27% in PCa patients at the first diagnosis in China, and even lower in European and American countries (8,9).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Measurements of peri-prostatic adipose tissue by MRI predict bone metastasis in patients with newly diagnosed prostate cancer

Liu,

Mao,

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

ObjectivesTo investigate the role of MRI measurements of peri-prostatic adipose tissue (PPAT) in predicting bone metastasis (BM) in patients with newly diagnosed prostate cancer (PCa).MethodsWe performed a retrospective study on 156 patients newly diagnosed with PCa by prostate biopsy between October 2010 and November 2022. Clinicopathologic characteristics were collected. Measurements including PPAT volume and prostate volume were calculated by MRI, and the normalized PPAT (PPAT volume/prostate volume) was computed. Independent predictors of BM were determined by univariate and multivariate logistic regression analysis, and a new nomogram was developed based on the predictors. Receiver operating characteristic (ROC) curves were used to estimate predictive performance.ResultsPPAT and normalized PPAT were associated with BM (P<0.001). Normalized PPAT positively correlated with clinical T stage(cT), clinical N stage(cN), and Grading Groups(P<0.05). The results of ROC curves indicated that PPAT and normalized PPAT had promising predictive value for BM with the AUC of 0.684 and 0.775 respectively. Univariate and multivariate analysis revealed that high normalized PPAT, cN, and alkaline phosphatase(ALP) were independently predictors of BM. The nomogram was developed and the concordance index(C-index) was 0.856.ConclusionsNormalized PPAT is an independent predictor for BM among with cN, and ALP. Normalized PPAT may help predict BM in patients with newly diagnosed prostate cancer, thus providing adjunctive information for BM risk stratification and bone scan selection.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Measurements of peri-prostatic adipose tissue by MRI predict bone metastasis in patients with newly diagnosed prostate cancer

Liu,

Mao,

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…(68% vs 98%). 23 Exact load of metastatic disease is essential to decide the management and PSMA PET is helpful in that aspect. Recently PSMA PET has also been evaluated for diagnosis and selection of patients for biopsy, showing promising results.…”

Section: Positron Emission Tomographymentioning

confidence: 99%

Prostate Carcinoma: Urologist's Perspective

Murugesan,

S.M

2024

Journal of Gastrointestinal and Abdominal Radiology

View full text Add to dashboard Cite

Prostate cancer management has undergone radical changes in recent times, due to early diagnosis in localized stage and availability of multiple treatment modalities. But the onus of selecting appropriate treatment rests with the urologist. Radiological investigations are immensely important in these patients. Measurement of prostate-specific antigen and its derivatives is the primary investigation in the diagnosis of prostate carcinoma. Ultrasonogram is of limited utility in prostate carcinoma. Magnetic resonance imaging provides extensive information to the treating physician regarding the approach and the treatment modality to be used in the management of prostate carcinoma. Radiological investigations are the cornerstones for efficient management of prostate carcinoma.

show abstract

“…Likewise, we conducted a metaanalysis that showed that there was a statistically significant effect modification in OS improvement between high-volume disease and low-volume metachronous presentation in patients receiving docetaxel-doublet therapy with no evidence of benefit in the latter subgroup (HR: 1.07; 95% CI: 0.75-1.54) [2 93--97 g Supported by findings from two phase III trials: LIGHTHOUSE [51], SPOTLIGHT [52] mHSPC, metastatic hormone sensitive prostate cancer. a [53,54].…”

Section: Metachronous Low-volume Prostate Cancermentioning

confidence: 99%

“…mHSPC, metastatic hormone sensitive prostate cancer.a[53,54].b[23,53].c[53,54].d[23,53,55].e[23,53,56–58].f[49,53,59].g[60].…”

Section: Identification Of Prognostic Groups In Clinical Practicementioning

confidence: 99%

Optimal systemic therapy in men with low-volume prostate cancer

Saxena,

Andrews,

Bryce

et al. 2024

Current Opinion in Urology

View full text Add to dashboard Cite

Purpose of review Low-volume prostate cancer is an established prognostic category of metastatic hormone-sensitive prostate cancer. However, the term is often loosely used to reflect the low burden of disease across different prostate cancer states. This review explores the definitions of low-volume prostate cancer, biology, and current evidence for treatment. We also explore future directions, including the impact of advanced imaging modalities, particularly prostate-specific membrane antigen (PSMA) positron emission tomography (PET) scans, on refining patient subgroups and treatment strategies for patients with low-volume prostate cancer. Recent findings Recent investigations have attempted to redefine low-volume disease, incorporating factors beyond metastatic burden. Advanced imaging, especially PSMA PET, offers enhanced accuracy in detecting metastases, potentially challenging the conventional definition of low volume. The prognosis and treatment of low-volume prostate cancer may vary by the timing of metastatic presentation. Biomarker-directed consolidative therapy, metastases-directed therapy, and de-escalation of systemic therapies will be increasingly important, especially in patients with metachronous low-volume disease. Summary In the absence of validated biomarkers, the management of low-volume prostate cancer as defined by CHAARTED criteria may be guided by the timing of metastatic presentation. For metachronous low-volume disease, we recommend novel hormonal therapy (NHT) doublets with or without consolidative metastasis-directed therapy (MDT), and for synchronous low-volume disease, NHT doublets with or without consolidative MDT and prostate-directed radiation. Docetaxel triplets may be a reasonable alternative in some patients with synchronous presentation. There is no clear role of docetaxel doublets in patients with low-volume disease. In the future, a small subset of low-volume diseases with oligometastases selected by genomics and advanced imaging like PSMA PET may achieve long-term remission with MDT with no systemic therapy.

show abstract

Bone Metastasis in Prostate Cancer: Bone Scan Versus PET Imaging

Cited by 8 publications

References 160 publications

Measurements of peri-prostatic adipose tissue by MRI predict bone metastasis in patients with newly diagnosed prostate cancer

Measurements of peri-prostatic adipose tissue by MRI predict bone metastasis in patients with newly diagnosed prostate cancer

Prostate Carcinoma: Urologist's Perspective

Optimal systemic therapy in men with low-volume prostate cancer

Contact Info

Product

Resources

About